Outcomes in COVID-19 obefazimod studies

0 0.5 1 1.5+ All studies -101% 1 305 Improvement, Studies, Patients Relative Risk Mortality -101% 1 305 Ventilation -26% 1 305 RCTs -101% 1 305 Late -101% 1 305 Obefazimod for COVID-19 c19early.org November 2025 Favorsobefazimod Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ miR-AGE Giavina-.. (DB RCT) -101% 2.01 [0.23-17.8] death 4/203 1/102 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.54 Late treatment -101% 2.01 [0.23-17.8] 4/203 1/102 101% higher risk All studies -101% 2.01 [0.23-17.8] 4/203 1/102 101% higher risk 1 obefazimod COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.54 Effect extraction pre-specified(most serious outcome) Favors obefazimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ miR-AGE Giavina-.. (DB RCT) -101% 2.01 [0.23-17.8] 4/203 1/102 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.54 Late treatment -101% 2.01 [0.23-17.8] 4/203 1/102 101% higher risk All studies -101% 2.01 [0.23-17.8] 4/203 1/102 101% higher risk 1 obefazimod COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.54 Favors obefazimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ miR-AGE Giavina-.. (DB RCT) -26% 1.26 [0.50-3.14] 15/203 6/102 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.64 Late treatment -26% 1.26 [0.50-3.14] 15/203 6/102 26% higher risk All studies -26% 1.26 [0.50-3.14] 15/203 6/102 26% higher risk 1 obefazimod COVID-19 mechanical ventilation result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.64 Favors obefazimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ miR-AGE Giavina-.. (DB RCT) -101% 2.01 [0.23-17.8] death 4/203 1/102 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.54 Late treatment -101% 2.01 [0.23-17.8] 4/203 1/102 101% higher risk All studies -101% 2.01 [0.23-17.8] 4/203 1/102 101% higher risk 1 obefazimod COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.54 Effect extraction pre-specified(most serious outcome) Favors obefazimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ miR-AGE Giavina-.. (DB RCT) -101% 2.01 [0.23-17.8] death 4/203 1/102 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.54 Late treatment -101% 2.01 [0.23-17.8] 4/203 1/102 101% higher risk All studies -101% 2.01 [0.23-17.8] 4/203 1/102 101% higher risk 1 obefazimod COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.54 Effect extraction pre-specified(most serious outcome) Favors obefazimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ miR-AGE Giavina-.. (DB RCT) -101% 2.01 [0.23-17.8] 4/203 1/102 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.54 Late treatment -101% 2.01 [0.23-17.8] 4/203 1/102 101% higher risk All studies -101% 2.01 [0.23-17.8] 4/203 1/102 101% higher risk 1 obefazimod COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.54 Favors obefazimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ miR-AGE Giavina-.. (DB RCT) -101% 2.01 [0.23-17.8] death 4/203 1/102 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.54 Late treatment -101% 2.01 [0.23-17.8] 4/203 1/102 101% higher risk All studies -101% 2.01 [0.23-17.8] 4/203 1/102 101% higher risk 1 obefazimod COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.54 Effect extraction pre-specified(most serious outcome) Favors obefazimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ miR-AGE Giavina-.. (DB RCT) -101% 2.01 [0.23-17.8] death 4/203 1/102 Improvement, RR [CI] Treatment Control miR-AGE Giavina-.. (DB RCT) -26% 1.26 [0.50-3.14] ventilation 15/203 6/102 miR-AGE Giavina-.. (DB RCT) -139% 2.39 [0.83-6.83] oxygen 19/203 4/102 Obefazimod COVID-19 outcomes c19early.org November 2025 Favors obefazimod Favors control